Institutes
Refine
Year of publication
Document Type
- Doctoral Thesis (307)
- Article (278)
- Preprint (38)
- Contribution to a Periodical (25)
- Book (17)
- Report (2)
Language
- English (514)
- German (152)
- Multiple languages (1)
Has Fulltext
- yes (667)
Is part of the Bibliography
- no (667)
Keywords
- RNA (12)
- SARS-CoV-2 (10)
- NMR spectroscopy (9)
- inflammation (9)
- photochemistry (9)
- NMR (8)
- Biochemistry (7)
- Cell biology (7)
- E2 enzyme (6)
- TRACT (6)
Institute
- Biochemie, Chemie und Pharmazie (667)
- Präsidium (42)
- Medizin (35)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (30)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (30)
- Biowissenschaften (23)
- MPI für Biophysik (15)
- Physik (12)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (5)
- Geowissenschaften / Geographie (4)
Objectives: The main objective of the present work was to combine in vitro and in silico tools to better understand the in vivo behavior of the immediate release (IR) formulation of zolpidem in the fasted and fed states.
Methods: The dissolution of zolpidem was evaluated using biorelevant media simulating the gastric and intestinal environment in the fasted and fed states. Additionally, the influence of high viscosity and high fat content on the release of zolpidem under fed state conditions was investigated. The in vitro results were combined with a physiologically based pharmacokinetic (PBPK) model constructed with Simcyp to simulate the zolpidem pharmacokinetic profile in both prandial states.
Key findings: In vitro biorelevant dissolution experiments representing the fasted and fed states, combined with PBPK modelling, were able to simulate the plasma profiles from the clinical food effect studies well. Experiments reflecting the pH and fat content of the meal led to a good prediction of the zolpidem plasma profile in the fed state, whereas increasing the viscosity of the gastric media led to an under-prediction.
Conclusions: This work demonstrates that the combination of biorelevant dissolution testing and PBPK modelling is very useful for understanding the in-vivo behavior of zolpidem in the fasted and fed states. This approach could be implemented in the development of other drugs exhibiting negative food effects, saving resources and bringing new drug products to the market faster.
Mesoporous silica has emerged as an enabling formulation for poorly soluble active pharmaceutical ingredients (APIs). Unlike other formulations, mesoporous silica typically does not inhibit precipitation of supersaturated API therefore, a suitable precipitation inhibitor (PI) should be added to increase absorption from the gastrointestinal (GI) tract. However, there is limited research about optimal processes for combining PIs with silica formulations. Typically, the PI is added by simply blending the API-loaded silica mechanically with the selected PI. This has the drawback of an additional blending step and may also not be optimal with regard to release of drug and PI. By contrast, loading PI simultaneously with the API onto mesoporous silica, i.e. co-incorporation, is attractive from both a performance and practical perspective. The aim of this study was to demonstrate the utility of a co-incorporation approach for combining PIs with silica formulations, and to develop a mechanistic rationale for improvement of the performance of silica formulations using the co-incorporation approach. The results indicate that co-incorporating HPMCAS with glibenclamide onto silica significantly improved the extent and duration of drug supersaturation in single-medium and transfer dissolution experiments. Extensive spectroscopic characterization of the formulation revealed that the improved performance was related to the formation of drug-polymer interactions already in the solid state; the immobilization of API-loaded silica on HPMCAS plates, which prevents premature release and precipitation of API; and drug-polymer proximity on disintegration of the formulation, allowing for rapid onset of precipitation inhibition. The data suggests that co-incorporating the PI with the API is appealing for silica formulations from both a practical and formulation performance perspective.
Background: Physiologically-based population pharmacokinetic modeling (popPBPK) coupled with in vitro biopharmaceutics tools such as biorelevant dissolution testing can serve as a powerful tool to establish virtual bioequivalence and set clinically relevant specifications. One of several applications of popPBPK modeling is in the emerging field of virtual bioequivalence (VBE), where it can be used to streamline drug development by implementing model-informed formulation design and to inform regulatory decision-making e.g., with respect to evaluating the possibility of extending BCS-based biowaivers beyond BCS Class I and III compounds in certain cases.
Methods: In this study, Naproxen, a BCS class II weak acid was chosen as the model compound. In vitro biorelevant solubility and dissolution experiments were performed and the resulting data were used as an input to the PBPK model, following a stepwise workflow for the confirmation of the biopharmaceutical parameters. The naproxen PBPK model was developed by implementing a middle-out approach and verified against clinical data obtained from the literature. Once confidence in the performance of the model was achieved, several in vivo dissolution scenarios, based on model-based analysis of the in vitro data, were used to simulate clinical trials in healthy adults. Inter-occasion variability (IOV) was also added to critical physiological parameters and mechanistically propagated through the simulations. The various trials were simulated on a “worst/best case” dissolution scenario and average bioequivalence was assessed according to Cmax, AUC and tmax.
Results: VBE results demonstrated that naproxen products with in vitro dissolution reaching 85% dissolved within 90 minutes would lie comfortably within the bioequivalence limits for Cmax and AUC. Based on the establishment of VBE, a dissolution “safe space” was designed and a clinically relevant specification for naproxen products was proposed. The interplay between formulation-related and drug-specific PK parameters (e.g., t1/2) to predict the in vivo performance was also investigated.
Conclusion: Over a wide range of values, the in vitro dissolution rate is not critical for the clinical performance of naproxen products and therefore naproxen could be eligible for BCS-based biowaivers based on in vitro dissolution under intestinal conditions. This approach may also be applicable to other poorly soluble acidic compounds with long half-lives, providing an opportunity to streamline drug development and regulatory decision-making without putting the patient at a risk.
The electron transport chain (ETC) is used by cells to create an electrochemical proton gradient which can be used by the ATP synthase to produce ATP. ETC, also called respiratory chain, is formed in mitochondria by four complexes (complex I-IV) and mediated by two electron carriers: cytochrome c and ubiquinone. Electrons are passed from one complex to another in a series of redox reactions coupling proton pumping from the negative (N) side of the membrane to the positive (P) side. Complex I can introduce electrons into the ETC by oxidizing NADH to NAD+ and reducing quinone (Q) to quinol (QH2). The process accomplishes pumping of four protons across the membrane. Complex II is another electrons entry point. It catalyzes the oxidation of succinate to fumarate while reducing Q to QH2. Complex III, also called cytochrome bc1 complex, can transfer the electrons from QH2 to cytochrome c and couple to proton pumping. In complex III the Q-cycle contributes four proton translocations: two protons are required for the reduction of one quinone to a quinol and two protons are released to the P side. Complex IV (cytochrome c oxidase), the terminal complex of the ETC, catalyzes the electron transfer to oxygen and pumps four protons to the P side. Structures of ETC complexes are available. However, the structure of a hyperthermophilic cytochrome bc1 complex has not been elucidated till now. Additionally, the dimeric crystal structure of cytochrome c oxidase from bovine has been discussed controversially.
To build up a functional complex, cofactors are required. The active site of A- and B-type cytochrome c oxidases contain the high spin heme a which is synthesized by the integral membrane protein heme A synthase (HAS). HAS can form homooligomeric complexes and its oligomerization is essential for the biological function of HAS. HAS is evolutionarily conserved among prokaryotes and eukaryotes. Despite its importance, little is known about the detailed structural properties of HAS oligomers.
During my PhD studies, I focused on the cytochrome c oxidase (AaCcO), the cytochrome bc1 complex (Aabc1) and the heme A synthase (AaHAS) from Aquifex aeolicus. This organism is one of the most hyperthermophilic ones and can live at extremely high temperatures, even up to 95 °C. Respiratory chain complexes provide energy for the metabolism of organisms, and their structures have been studied extensively in the past few years. However, there has been a lack of atomic structures of complexes from hyperthermophilic and ancient bacteria, so little is known about the mechanism of these macromolecular machines under hyperthermophilic conditions. Therefore, my PhD studies had four main objectives: 1) to structurally and functionally characterize AaCcO, 2) to reveal the mechanism of Aabc1 thermal stability based on its structure, 3) to determine the oligomerization of AaHAS, 4) to provide valuable insights into the relationship between function and oligomerization of AaHAS.
1) Structure of AaCcO
Heme-copper oxidases (HCOs) catalyze the oxygen reduction reaction being the terminal enzymes in the plasma membranes in many prokaryotes or of the aerobic respiratory chain in the inner mitochondrial membrane. By coupling this exothermic reaction to proton pumping across the membrane to the P side, they contribute to the establishment of an electrochemical proton gradient. The energy in the proton electrochemical proton gradient is used by the ATP synthase to generate ATP. HCOs are classified into three major families: A, B and C, based on phylogenetic comparisons. The well-studied aa3-type cytochrome c oxidase from Paracoccus denitrificans (P. denitrificans) represents A-family HCOs. So far, the only available structure of the ba3-type cytochrome c oxidase from Thermus thermophilus represents the B-family of HCOs. This family contains a number of bacterial and archaeal oxidases. The C-family contains only cbb3-type cytochrome c oxidases.
The AaCcO is one of the ba3-type cytochrome c oxidases. Based on the genomic DNA sequence analysis, it has been revealed that A. aeolicus possesses two operons coding for cytochrome c oxidases (two different subunit I genes, two different subunit II genes and one subunit III gene). So far, only subunits CoxB2 and CoxA2 were identified. The presence of the additional subunit IIa was reported in 2012. Moreover, a previous paper reported that AaCcO can use horse heart cytochrome c and decylubiquinol as electron donors and the typical cytochrome c oxidase inhibitor cyanide does not block the reaction completely.
In the course of my PhD studies, I performed heterologous expression of AaCcO in Pseudomonas stutzeri (P. stutzeri) and co-expression with AsHAS in Escherichia coli, respectively. The subcomplex CoxA2 and CoxB2 can be purified from P. stutzeri, however, it lacks heme A. Additionally, a protocol for the heterologous production of cytochrome c555 from A. aeolicus was established. In parallel, I also purified the AaCcO from native membranes according to previously reported methods with some modifications. The activity of AaCcO with its native substrate, cytochrome c555, was 14 times higher than with horse heart cytochrome c.
To enable a detailed investigation and comparison of AaCcO and other cytochrome c oxidases, the cryo-EM structure of AaCcO was determined to 3.4 Å resolution. It shows that the three subunits CoxA2, CoxB2, and IIa are tightly bound together to form a dimer in the membrane. Surprisingly, CoxA2 contains two additional TMHs (TMH13 and TMH14) to enhance the protein stability. The cofactors heme a3, heme b, CuA and CuB are also identified. Interestingly, two molecules of 1,4-naphthoquinone and cardiolipin were observed in the dimer interface. Based on the structure analysis, the AaCcO possesses only the K-pathway for proton delivery to the active site and proton pumping.
...
Uncaging approach, native membrane dynamics and lipidic cubic phases in biomolecular solid-state NMR
(2019)
It was previously shown for the Escherichia coli diacylglycerol kinase (DgkA) that enzyme-reactions at the membrane interface can be monitored by solid-state NMR. However, such studies can face problems due to limited accessibility of the active sites: Natural substrates for membrane enzymes, but also ligands for membrane proteins or lipid mediators, are either partitioning into the membrane and cannot be added easily, or if soluble exhibit accessibility restrictions, as they cannot freely pass through lipid bilayers. This situation complicates quantitative kinetic analysis of biochemical processes such as enzyme activity, ligand binding, but also oligomerization or folding reactions in the membrane or at its interface under MAS NMR conditions.
To overcome these limitations the feasibility and possible advantages of the uncaging approach as a new tool for biomolecular solid-state NMR to trigger reactions by light have been explored. DgkA’s enzymatic activity, exemplary of a biochemical process on the membrane interface, was thereby triggered in situ during MAS by light-induced release of its substrates that were rendered inactive with photolabile protecting groups. To be capable of uncaging sufficient amounts of substrate during MAS to follow the enzymatic reaction via 31P real-time NMR measurements, several illumination variants including an existing illumination setup to study retinal proteins under cryogenic conditions via DNP enhanced NMR were tested. As uncaging of micromole amounts of substrates requires a higher flux compared to initiation of a photocycle in retinal proteins, a new illumination setup was built with Bruker Biospin and Leoni Fibertech. It consists of a modified MAS probe and a suitable fiber bundle, allowing to efficiently couple light from high power LEDs into a sapphire rotor containing the sample, without disturbing the magnetic field homogeneity or sample rotation. By reducing the sample volume to the illuminated area up to 60 mM ATP were released by uncaging NPE ATP to initiate DgkA’s activity in several tested membrane mimetics. These mimetics included liposomes and bicelles, which are well established in the field of biomolecular solid state NMR as well as the optically transparent lipidic cubic phase of monoolein, widely used in membrane protein crystallography, but not yet well characterized as membrane mimetic under MAS conditions. A unique and powerful but compared to time and spatial resolution often underrepresented advantage of the uncaging approach for biophysical studies has been demonstrated by successful uncaging of a non-miscible lipid substrate to trigger DgkA’s kinase reaction: Initiation of processes that cannot easily be triggered by mixing. Examples of these are reactions involving highly hydrophobic, membrane partitioning compounds including lipid substrates, ligands or interaction partners, but also oligomerization or folding of biomacromolecules. The herein performed experiments therefore serve as a first demonstration of the uncaging approach’s feasibility and compatibility with a wide variety of membrane mimetics and give a first indication of its potential for a variety of biomolecular solid state NMR experiments.
As high accessibility for solutes has been a second focus for the choice of membrane mimetics, DgkA’s activity in the lipidic cubic phases of monoacylglycerols with its two continuous networks of water channels has been further characterized. Kinetic parameters obtained from 31P real time solid state NMR experiments revealed that DgkA’s activity is similar to activities obtained in swollen cubic phases in a bath solution with wider water channels. Diffusion of ATP in a non swollen cubic phase was however strongly reduced compared to ATP in solution as diffusion measurements showed. Therefore, saturation of the enzyme required distinctly higher ATP concentrations. These results thereby underline the advantage of a non invasive and label free method like NMR to directly gain information about enzymatic reactions of immobilized enzymes in porous materials. The obtained wealth of information from 31P real time NMR experiments and biochemical assays in different membrane mimetics in presence and absence of lipid substrates and activators also provided further insight into DgkA’s enzymatic activity. It confirms ATP binding and hydrolysis in the absence of a lipid substrate, in agreement with the proposed mode of substrate binding, and allowed to estimate the in vivo relevance of previously observed ATPase activity in liposomes.
Further exploration of the cubic phase as membrane mimetic for protein solid state NMR revealed its high stability under MAS at elevated temperatures and capacity to reconstitute sufficient amounts of DgkA. Unlike monoolein, DgkA was cross-polarizable in a cubic phase and exhibited similar dynamics compared to DgkA reconstituted into liposomes, allowing to acquire the herein shown dipolar coupling based 2D protein spectra. As lipidic cubic phases are not containing phospholipids, monoacylglycerols could be especially useful as membrane mimetics for 31P correlation spectra. Initial experiments under DNP conditions, where in liposomes line broadening causes severe overlap of phospholipid signals and unspecific cross polarization highlight this aspect.
In summary, herein reported results of the experiments performed with lipidic cubic phases demonstrate that they are robust and versatile membrane mimetics. They could be of advantage for a variety of solid-state NMR experiments where either optical transparency for efficient illumination is desired, accessibility for solutes and membrane components under MAS is required, or interference of phosphorous signals of other membrane mimetics must be avoided.
In the second chapter of this thesis 1H solid-state NMR as a label free method to probe membrane order and dynamics directly within a cellular and disease relevant context was used to observe the effects of soluble epoxide hydrolase (sEH) encoding gene knock-outs on membrane dynamics. Knock-out of the sEH encoding gene changed the overall membrane dynamics in the physiological temperature range of native membranes derived from mouse brains, making the bulk membrane more dynamic. To confirm that these effects are related to the enzymatic activity of sEH, substrates and products of sEH were added to evaluate their effects on membrane dynamics. 19,20 dihydroxydocosapentaenoic acid (DHDP), a product of sEH, partially reversed the knock out phenotype in a concentration dependent manner whereas the substrate 19,20 epoxydocosapentaenoic acid did not cause any effects. As both polyunsaturated fatty acids did not show differences in phase behavior in a simple phospholipid bilayer these results provide evidence that the previously observed concentration dependent DHDP induced relocation of cholesterol away from detergent resistant lipid raft fractions is associated with alteration of membrane dynamics. Therefore, also the effect of cholesterol removal via cyclodextrin on membrane dynamics was analyzed. Removal of cholesterol led to a similar temperature profile of wild type and knock out membranes thereby supporting the hypothesis that DHDP induced relocation of cholesterol is causing altered membrane dynamics. These alterations have been shown by the lead authors of the collaborative research project to induce relocation of various membrane proteins and are involved in the development of diabetic retinopathy. Furthermore, in this context inhibition of sEH has been shown to inhibit diabetic retinopathy and proposed as target for prevention of one of the leading causes of blindness in the developed world.
In the context of data science, data projection and clustering are common procedures. The chosen analysis method is crucial to avoid faulty pattern recognition. It is therefore necessary to know the properties and especially the limitations of projection and clustering algorithms. This report describes a collection of datasets that are grouped together in the Fundamental Clustering and Projection Suite (FCPS). The FCPS contains 10 datasets with the names "Atom", "Chainlink", "EngyTime", "Golfball", "Hepta", "Lsun", "Target", "Tetra", "TwoDiamonds", and "WingNut". Common clustering methods occasionally identified non-existent clusters or assigned data points to the wrong clusters in the FCPS suite. Likewise, common data projection methods could only partially reproduce the data structure correctly on a two-dimensional plane. In conclusion, the FCPS dataset collection addresses general challenges for clustering and projection algorithms such as lack of linear separability, different or small inner class spacing, classes defined by data density rather than data spacing, no cluster structure at all, outliers, or classes that are in contact. This report describes a collection of datasets that are grouped together in the Fundamental Clustering and Projection Suite (FCPS). It is designed to address specific problems of structure discovery in high-dimensional spaces.
Introduction: In the development of bio-enabling formulations, innovative in vivo predictive tools to understand and predict the in vivo performance of such formulations are needed. Etravirine, a non-nucleoside reverse transcriptase inhibitor, is currently marketed as an amorphous solid dispersion (Intelence® tablets). The aims of this study were 1) to investigate and discuss the advantages of using biorelevant in vitro setups in simulating the in vivo performance of Intelence® 100 mg and 200 mg tablets, in the fed state, 2) to build a Physiologically Based Pharmacokinetic (PBPK) model by combining experimental data and literature information with the commercially available in silico software Simcyp® Simulator V17.1 (Certara UK Ltd.), and 3) to discuss the challenges when predicting the in vivo performance of an amorphous solid dispersion and identify the parameters which influence the pharmacokinetics of etravirine most.
Methods: Solubility, dissolution and transfer experiments were performed in various biorelevant media simulating the fasted and fed state environment in the gastrointestinal tract. An in silico PBPK model for healthy volunteers was developed in the Simcyp® Simulator, using in vitro results and data available from the literature as input. The impact of pre- and post-absorptive parameters on the pharmacokinetics of etravirine was investigated using simulations of various scenarios.
Results: In vitro experiments indicated a large effect of naturally occurring solubilizing agents on the solubility of etravirine. Interestingly, supersaturated concentrations of etravirine were observed over the entire duration of dissolution experiments on Intelence® tablets. Coupling the in vitro results with the PBPK model provided the opportunity to investigate two possible absorption scenarios, i.e. with or without implementation of precipitation. The results from the simulations suggested that a scenario in which etravirine does not precipitate is more representative of the in vivo data. On the post-absorptive side, it appears that the concentration dependency of the unbound fraction of etravirine in plasma has a significant effect on etravirine pharmacokinetics.
Conclusions: The present study underlines the importance of combining in vitro and in silico biopharmaceutical tools to advance our knowledge in the field of bio-enabling formulations. Future studies on other bio-enabling formulations can be used to further explore this approach to support rational formulation design as well as robust prediction of clinical outcomes.
The endosteal bone marrow niche and vascular endothelial cells provide sanctuaries to leukemic cells. In murine chronic myeloid leukemia (CML) CD44 on leukemia cells and E-selectin on bone marrow endothelium are essential mediators for the engraftment of leukemic stem cells (LSC). We hypothesized that non-adhesion of CML-initiating cells to E-selectin on the bone marrow endothelium may lead to superior eradication of LSC in CML after treatment with imatinib than imatinib alone. Indeed, here we show that treatment with the E-selectin inhibitor GMI-1271 in combination with imatinib prolongs survival of mice with CML via decreased contact time of leukemia cells with bone marrow endothelium. Non-adhesion of BCR-ABL1+ cells leads to an increase of cell cycle progression and an increase of expression of the hematopoietic transcription factor and protooncogene Scl/Tal1 in leukemia-initiating cells (LIC). We implicate SCL/TAL1 as indirect phosphorylation target of BCR-ABL1 and as a negative transcriptional regulator of CD44 expression. We show that increased SCL/TAL1 expression is associated with improved outcome in human CML. These data demonstrate the BCR-ABL1-specific, cell-intrinsic pathways leading to altered interactions with the vascular niche via the modulation of adhesion molecules - a strategy therapeutically exploitable in future.
In der vorliegenden Arbeit konnte die Entwicklung und Evaluierung einer neuen Apparatur zur Untersuchung der Freisetzungseigenschaften von kolloidalen Arzneiträgern erfolgreich umgesetzt werden. Verschiedene Prototypen und Versionen des Dispersion Releasers konnten entwickelt und mit Hilfe der Werkstatt des Fachbereiches 14 umgesetzt werden. Dabei ermöglicht die letzte Optimierung (Version 3) den Einsatz beider relevanter Dialysemembranen. Sowohl regenerierte Cellulose als auch Celluloseacetat konnten zur Freisetzungsuntersuchung eingesetzt werden. Vorteilhaft ist diese Optionalität vor allem, da auf diese Weise Partikelsysteme und Wirkstoffe mit unterschiedlichen physiko-chemischen Eigenschaften in der gleichen Apparatur auf das Freigabeverhalten untersucht werden können. Darüber hinaus hat der Dispersion Releaser das Potential, sich im Bereich der Freisetzungsuntersuchungen kolloidaler Arzneiträger über den Arbeitskreis von Dr. Wacker hinaus zu einem bevorzugten Testsystem zu entwickeln. In diesem speziellen Gebiet der Freisetzungsuntersuchung von kolloidalen Arzneiträgern wie Nanopartikeln oder Liposomen existiert bisher keine Apparatur, die als sogenannter Gold-Standard angesehen werden kann. Untersuchungen mittels der Durchflusszelle, dem A4D oder Sample & Separate Methoden im Labormaßstab unterliegen kaum standardisierbaren Bedingungen und diversen Limitierungen. Der Dispersion Releaser ist einfach zu handhaben und mit wenig Aufwand in die Freisetzungsapparatur 2 nach Ph. Eur. einzubauen. Zu den zahlreichen Vorteilen gehören außerdem die Kontrolle der Rührgeschwindigkeit sowie der Temperatur und der mögliche Probenzug in beiden Kompartimenten der Dialysezelle. Würden mehr Freisetzungsuntersuchungen von kolloidalen Arzneiträgern mit der gleichen, im besten Falle standardisierten, Apparatur durchgeführt, so würde dies die Vergleichbarkeit der Resultate erheblich verbessern.
Die präparierten Modellarzneiformen der beiden Arzneistoffe mTHPC und Flurbiprofen konnten die Funktionalität des Dispersion Releasers mittels der erhobenen Freisetzungsprofile belegen. Es konnten sowohl schnell als auch langsamer freisetzende kolloidale Formulierungen produziert und identifiziert werden. Als Standard-Freisetzungsmedium diente ein 10 mM Phosphatpuffer versetzt mit Natrium- und Kaliumchlorid bei pH 7,4. Dieser im Hinblick auf pH-Wert, Osmolalität und Pufferkapazität dem Blut angepasste Puffer lieferte reproduzierbare Freisetzungsprofile für alle untersuchten Partikelsysteme. Der Zusatz von Plasmaproteinen erfolge durch Zufügen von FBS zu diesem Standardpuffersystem oder durch Verwendung des im Ph. Eur. gelisteten Phosphatpuffers pH 7,2 mit Rinderalbumin. Der Effekt der im Plasma natürlicherweise enthaltenen Komponenten, insbesondere der Plasmaproteine, auf das Freisetzungsprofil zeigt in dieser Arbeit, dass -wie erwartet- die Freisetzungseigenschaften in komplexen, bzw. physiologischen Medien deutlich von denen in einfachen Puffersystemen abweichen können. Die Anwesenheit von Plasmaproteinen führte zu einer veränderten Freisetzungsrate, sowohl im Falle von Flurbiprofen als auch im Falle von mTHPC. Für mTHPC konnte außerdem der Zusatz von lösungsvermittelndem Methyl-ß-cyclodextrin zum Freisetzungsmedium etabliert werden. Gegenüber üblicherweise eingesetzten Tensiden verändert dieses cyclische Zuckermolekül die Oberflächenspannung des Mediums und damit die Benetzbarkeit der Partikel nicht.
Die mittels Dispersion Releaser und Dialysesack erhobenen Freisetzungsdaten des Wirkstoffes Flurbiprofen wurden in Zusammenarbeit mit Frau Dr. Li Kirsamer einer mathematischen Auswertung unterzogen. Auf diese Weise konnte zunächst das Freisetzungsprofil beider Kompartimente der Dialyse dargestellt werden, wodurch weitere Erkenntnisse der Qualität des kolloidalen Trägers und seiner Eignung für den jeweiligen Arzneistoff abgeleitet werden können. Die Auswertung an Hand dieses Modells berücksichtigt zwar die Fraktion des freigesetzten Wirkstoffes in beiden Kompartimenten, ermittelt jedoch keine theoretische Freisetzungsrate welche ohne Membrankinetik messbar wäre. Dies wäre in der Auswertung von Freisetzungsdaten ebenfalls von Interesse, konnte jedoch im Rahmen dieser Arbeit nicht näher untersucht werden. Berechnungen wie diese können in weiterführenden Arbeiten möglicherweise dazu dienen, in vitro Freisetzungsdaten mit Plasmaprofilen zu korrelieren. Mit dem Erwerb der Rechte an dem Dispersion Releaser durch die Firma Pharma Test Apparatebau AG im Jahr 2016 wurde der Weg für eine mögliche breite und auch kommerzielle Nutzung der neuartigen Apparatur eingeleitet. Diese Transaktion und die andauernde Kooperation zwischen Pharmatest und dem Arbeitskreis von Herrn Prof. Dr. Wacker soll die erfolgreiche Beantwortung der Fragestellungen innerhalb der vorliegenden Arbeit mit dem Titel „Entwicklung einer Apparatur zur in vitro Testung der Wirkstofffreisetzung aus kolloidalen Arzneistoffträgern“ hervorheben.
The members of the multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) transporter superfamily mediate export of a wealth of molecules of physiological and pharmacological importance. According to the Transporter Classification Database (TCDB), the MOP superfamily is mainly categorized into six distantly related families functionally characterized families: the multidrug and toxic compound extrusion (MATE), the polysaccharide transporter (PST), the oligosaccharidyl-lipid flippase (OLF), the mouse virulence factor (MVF) the agrocin 84 antibiotic exporter (AgnG), and the progressive ankylosis (Ank) family. Among these, the multidrug resistance MATE family transporters are most ubiquitous, being present in all domains of life: Archaea, Bacteria and Eukarya. As secondary active transporters, they utilize transmembrane electrochemical ion gradients of Na+ and/or H+ in order to drive the efflux of xenobiotics or cytotoxic metabolic waste products with specificity mainly for polyaromatic and cationic substrates. Active efflux of drugs and toxic compounds carried out by multidrug transporters is one of the strategies developed by bacterial pathogens to confer multidrug resistance. MATE proteins provide resistance to, e.g., fluoroquinolone, aminoglycoside antibiotics, and anticancer chemotherapeutical agents, thus serving as promising pharmacological targets for tackling a severe global health issue. Based on their amino acid sequence similarity, the MATE family members are classified into the NorM, the DNA-damage-inducible protein F (DinF), and the eukaryotic subfamilies. Structural information on the alternate conformational states and knowledge of the detailed mechanism of the MATE transport are of great importance for the structure-aided drug design. Over the past decade, the crystal structures of representative members of the NorM, DinF and eukaryotic subfamilies have been presented. They all share similar overall architecture comprising 12 transmembrane helices (TMs) divided into two domains, the N-terminal domain (TMs 1-6) and the C-terminal domain (TMs 7-12), connected by a cytoplasmic loop between TM6 and TM7 (Fig. II.1). Since all available MATE family structures are known only in V-shaped outward-facing states with the central binding cavity open towards the extracellular side, a detailed understanding of the complete transport cycle has remained elusive. In order to elucidate the underlying steps of the MATE transport mechanism, structures of distinct intermediates, particularly inward-facing conformation, are required.In my PhD project, structural and functional studies have been performed on a MATE family (DinF subfamily) transporter, PfMATE, from the hyperthermophilic and anaerobic archaeon Pyrococcus furiosus. This protein was produced homologously in Pyrococcus furiosus as well as heterologously in Escherichia coli, and used for the subsequent purification and crystallization trials by the vapor diffusion (VD) and lipidic cubic phase (LCP) method. To the best of my knowledge, PfMATE is the first example of a successful homologous production of a membrane protein in P. furiosus. Due to the very low final amount of the purified protein from the native source, the heterologously produced PfMATE samples were typically used for the extensive structural studies. Crystal structures of PfMATE have been previously determined in an outward-facing conformation in two distinct states (bent and straight) defined on the arrangement of TM1. A pH dependent conformational transition of this helix regulated by the protonation state of the conserved aspartate residue Asp41 was proposed. However, it has been discussed controversially, leading to the hypothesis about TM1 bending to be rather affected by interactions with exogenous lipids (monoolein) present under the crystallization conditions. Based on these open questions, an experimental approach to investigate the role of lipids as structural and functional modulators of PfMATE has been taken in the course of my PhD project. The interplay between membrane proteins and lipids can affect membrane protein topology, structure and function. Considering differences between archaeal and bacterial lipid composition, cultivation of P. furiosus cells and extraction of its lipids was followed by the mass spectrometry (MS) based lipidomics for identification of individual lipid species in the archaeal extract. In order to assess the effects of lipids on PfMATE, different lipid molecules were used for co-purification and co-crystallization trials. This dissertation presents a workflow leading to the structure determination of a MATE transporter in the long sought-after inward-facing state, which has been achieved upon purification and crystallization of the heterologously produced PfMATE in the presence of lipids from its native source P. furiosus. Also, the PfMATE outward-facing state obtained from the crystals grown at the acidic pH conditions sheds light on the previously proposed pH-dependent structural alterations within TM1. It is interesting to note that the inward and outward-facing states of PfMATE were obtained from the crystals grown under similar conditions, but in the presence and absence of native lipids, respectively. This observation supports the hypothesis about physiologically relevant lipids to act as conformational modulators or/and a new class of substrates, expanding the substrate spectrum of the MATE family transporters. Comparative analysis of two PfMATE states reveals that transition from the outward to the inward-facing state involves rigid body movements of TMs 2-6 and 8-12 to form an inverted V, facilitated by a loose binding of TMs 1 and 7 to their respective bundles and their conformational flexibility. Local fluctuations within TM1 in the inward-facing structure, including bending and unwinding in the intracellular half of the helix, invoke its highly flexible nature, which is suitable for ion and substrate gating.
...